Discover Thomson Reuters
Posted
Nestle will pay $2 billion to buy the remaining stake in Aimmune Therapeutics Inc, gaining full ownership of the first U.S.-approved peanut allergy treatment. Conway G. Gittens reports.
01:00
01:28
02:17
02:11
00:00
01:38
01:03
02:05
02:19
01:30
01:58
01:40
02:03
02:20
01:49
01:57
02:35
01:56
01:43